Table 2 Baseline and transplant-related characteristics
From: Graft versus host disease-related eosinophilic fasciitis: cohort description and literature review
GROUP 1 fasciitis absent | GROUP 2 fasciitis present | p | |
|---|---|---|---|
Characteristics | N (%)/median (range) | N (%)/median (range) | |
Total, n | 43 | 39 | |
Patient age at enrollment, years (range) | 52 (18–74) | 56 (6–78) | ns |
Patient gender | |||
Male/female | 31 (72.1%)/12 (27.9%) | 22 (56.4%)/17 (43.6%) | 0.138 |
Diagnosis | |||
AML/NHL/ALL | 11 (25.6%)/8 (18.6%)/9 (20.9%) | 17 (43.6%)/9 (23.1%)/4 (10.3%) | |
MDS/MPS | 8 (18.6%)/1 (2.3%) | 5 (12.8%)/2 (5.1%) | 0.341 |
Others (HL, MM, CML, LLC) | 6 (13.9%) | 2 (5.1%) | |
HCT type | |||
Related | 28 (65.1%) | 21 (53.8%) | |
Unrelated | 15 (34.9%) | 18 (46.2%) | 0.326 |
HLA matching | |||
Identical | 39 (90.7%) | 37 (94.9%) | |
1 Mismatched | 3 (7.0%) | 1 (2.6%) | 0.651 |
Haploidentical | 1 (2.3%) | 1 (2.6%) | |
Conditioning regimen | |||
Reduced intensity | 27 (62.8%) | 21 (53.8%) | 0.157 |
Myeloablative | 16 (37.2%) | 18 (46.2%) | |
Stem cell graft source | |||
Mobilized blood cells | 42 (97.7%) | 38 (97.4%) | |
Bone marrow | 0 (0%) | 1 (2.8%) | 0.366 |
Umbilical cord blood | 1 (2.3%) | 0 (0%) | |
GVHD prophylaxis | |||
TACRO + RAPA ± MMF | 22 (51.1%) | 17 (43.5%) | |
TACRO/CSA + MTX | 6 (14.0%) | 6 (15.4%) | |
TACRO + MTX + ATG | 11 (25.6%) | 15 (38.4%) | 0.214 |
TACRO + MMF + Cy | 4 (9.3%) | 1 (2.6%) | |
Prior acute GVHD | 33 (76.7%) | 27 (69.2%) | |
Grade 2–4 | 25 (58.1%) | 22 (56.4%) | 0.053 |
Grade 3–4 | 8 (18.6%) | 5 (12.8%) | |